Literature DB >> 2417551

Clinical applications of antiviral agents for chemophrophylaxis and therapy of respiratory viral infections.

F G Hayden.   

Abstract

Table III summarizes clinical applications of antiviral agents in respiratory viral infections. (table: see text) For influenza A virus infections, both oral amantadine and rimantadine are effective when used for seasonal prophylaxis and for prophylaxis in institutional populations. Both of these drugs, as well as aerosolized ribavirin, have antiviral and therapeutic effects in uncomplicated influenza. It remains to be determined whether any of these modalities or possibly their combined use [44] will be useful in treating severe influenza hospitalized patients or whether they can prevent the development of complications in high risk patients. Unfortunately, there is no parenteral formulation of amantadine or rimantadine for use in critically ill patients. Aerosolized ribavirin has also been shown to have modest therapeutic effects in influenza B virus infection. However, a major need exists for an antiviral which is active against influenza B virus and which can be used on an outpatient basis. Controlled clinical trials have shown that aerosolized ribavirin therapy improves arterial oxygenation and modifies the severity of respiratory syncytial virus bronchiolitis and pneumonia [3,5]. Its role in treating life-threatening disease or in modifying the long-term sequelae of RSV infections are unknown at the present time. Again, a specific antiviral agent is needed for outpatient use in preventing or treating RSV infections. Finally, after over a decade of work since the original observation that intranasal interferon could prevent experimental rhinovirus infection [11], recent studies have established that intranasal rIFN-a2 is effective in the postexposure prophylaxis of rhinovirus colds in families [42]. This strategy needs to be studied with regard to the prevention of infection and its complications in high risk patients and it remains to be determined whether intranasal interferon will have therapeutic activity in established colds.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2417551     DOI: 10.1016/s0166-3542(85)80033-4

Source DB:  PubMed          Journal:  Antiviral Res        ISSN: 0166-3542            Impact factor:   5.970


  6 in total

1.  Affinity of Rimantadine Enantiomers against Influenza A/M2 Protein Revisited.

Authors:  Antonios Drakopoulos; Christina Tzitzoglaki; Chulong Ma; Kathrin Freudenberger; Anja Hoffmann; Yanmei Hu; Günter Gauglitz; Michaela Schmidtke; Jun Wang; Antonios Kolocouris
Journal:  ACS Med Chem Lett       Date:  2017-01-27       Impact factor: 4.345

2.  Unraveling the Binding, Proton Blockage, and Inhibition of Influenza M2 WT and S31N by Rimantadine Variants.

Authors:  Antonios Drakopoulos; Christina Tzitzoglaki; Kelly McGuire; Anja Hoffmann; Athina Konstantinidi; Dimitrios Kolokouris; Chunlong Ma; Kathrin Freudenberger; Johanna Hutterer; Günter Gauglitz; Jun Wang; Michaela Schmidtke; David D Busath; Antonios Kolocouris
Journal:  ACS Med Chem Lett       Date:  2018-01-29       Impact factor: 4.345

3.  Binding and Proton Blockage by Amantadine Variants of the Influenza M2WT and M2S31N Explained.

Authors:  Christina Tzitzoglaki; Anna Wright; Kathrin Freudenberger; Anja Hoffmann; Ian Tietjen; Ioannis Stylianakis; Felix Kolarov; David Fedida; Michaela Schmidtke; Günter Gauglitz; Timothy A Cross; Antonios Kolocouris
Journal:  J Med Chem       Date:  2017-02-15       Impact factor: 8.039

Review 4.  Inhaled anti-infective chemotherapy for respiratory tract infections: successes, challenges and the road ahead.

Authors:  Tony Velkov; Nusaibah Abdul Rahim; Qi Tony Zhou; Hak-Kim Chan; Jian Li
Journal:  Adv Drug Deliv Rev       Date:  2014-11-12       Impact factor: 15.470

Review 5.  Innate immunity for biodefense: a strategy whose time has come.

Authors:  Catherine Amlie-Lefond; David A Paz; Mary P Connelly; Gary B Huffnagle; Kyle S Dunn; Noel T Whelan; Harry T Whelan
Journal:  J Allergy Clin Immunol       Date:  2005-10-24       Impact factor: 10.793

Review 6.  Picornavirus inhibitors.

Authors:  L Carrasco
Journal:  Pharmacol Ther       Date:  1994       Impact factor: 12.310

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.